Assertio Holdings, Inc. (ASRT) 股票分析

公司概述

Assertio Holdings, Inc. operates within the healthcare sector, specifically focusing on the drug manufacturing industry for specialty and generic pharmaceuticals, providing various therapeutic products to patients in the United States. The company's portfolio includes specific formulations such as INDOCIN, an oral and suppository solution designed to treat moderate to severe rheumatoid arthritis, including acute flares of chronic disease and ankylosing spondylitis. As a market participant with a market capitalization of $116.14 million and an annual revenue of $118.71 million over the trailing twelve months, Assertio Holdings maintains a workforce of 53 employees. These valuation and revenue figures indicate that the company functions as a micro-cap entity with a revenue scale comparable to its market capitalization, suggesting a pricing structure where the market values the firm nearly one-for-one against its top-line performance.

财务健康

The financial performance of the company over the trailing twelve months shows a revenue of $118.71 million, a net income of -$30.375 million, and an EBITDA of $12.78 million. The significant gap between the positive EBITDA of $12.78 million and the negative net income of -$30.375 million reveals a substantial cost structure driven by non-operating expenses or interest costs that outweigh operating profits. Free cash flow stands at -$16.58225 million, indicating that the company is currently consuming cash rather than generating liquidity, which constrains its immediate financial flexibility and reliance on external capital or internal reserves. The gross margin is reported at 70.2%, reflecting a high-cost structure where the majority of revenue is retained after cost of goods sold, yet this is offset by operating and profit margins of -105.2% and -25.6% respectively. The negative operating margin of -105.2% suggests that operating expenses are significantly higher than operating income, while the profit margin of -25.6% confirms that non-operating items are contributing to the overall loss. On the balance sheet, the company holds $63.41 million in cash against $40.25 million in debt, resulting in a debt-to-equity ratio of 42.84, which indicates a highly leveraged position relative to shareholders' equity. The current ratio of 1.70 suggests adequate short-term liquidity, as current assets are more than 1.7 times current liabilities, providing a buffer against immediate obligations. Return on equity is -28.3% and return on assets is -3.9%, metrics that reveal management has not yet generated returns on capital employed, highlighting the challenges in optimizing asset efficiency and shareholder value creation in the current operational phase.

估值评估

The valuation metrics for Assertio Holdings, Inc. include a trailing P/E ratio that is N/A due to losses, contrasted with a forward P/E of 2.51. The disparity between a non-existent trailing earnings multiple and a low forward multiple of 2.51 implies that the market expects a significant turnaround in earnings trajectory where future earnings will be positive enough to support a multiple. The price-to-book ratio is 1.23, indicating that the stock trades at a 23% premium over its book value, suggesting the market assigns some intangible value or future growth potential despite current losses. Alternative valuation measures such as the price-to-sales ratio of 0.98 and an EV/EBITDA of 7.28 provide context for the stock's pricing relative to its sales generation and enterprise value. The 52-week price range spans from a low of $7.65 to a high of $20.45, and the current trading price sits below the 52-week high, reflecting recent volatility. The beta value of 0.43 indicates that the stock's price volatility is significantly lower than the broader market, moving with less intensity than the overall market index.

Growth & Income

Revenue growth over the year-over-year period is reported at -57.9%, while earnings growth is N/A due to the lack of prior year profitability for comparison. The contraction in revenue coupled with the absence of positive earnings growth highlights a period of business contraction or strategic transition rather than expansion. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders and instead retains all earnings. Given the negative net income and negative free cash flow, the concept of reinvesting earnings into growth is limited by the company's current cash burn rather than active capital allocation for expansion. The overall growth and income profile is characterized by significant revenue decline, negative profitability, and an absence of dividend income, presenting a high-risk financial structure reliant on future operational improvements to restore growth and cash generation capabilities.